NVCR — NovoCure Ltd

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1645113 · Jersey
Last close
$18.26
Market Cap
$2.11B
52W High
$18.92
52W Low
$10.14
ADV30
1,739,609
Next earnings
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 174,055,000 135,126,000 -67,420,000 -71,138,000 787,926,000 87,527,000 457,209,000
Dec 2025 174,350,000 132,193,000 -40,393,000 -24,499,000 804,326,000 93,548,000 463,860,000
Sep 2025 167,204,000 122,475,000 -36,021,000 -37,270,000 1,361,194,000 342,119,000 1,019,861,000
Jun 2025 158,805,000 117,333,000 -39,521,000 -40,139,000 1,245,875,000 149,624,000 896,434,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-26,883,000
Investing CF
$451,495,000
Financing CF
$-456,756,000
CapEx
$-21,189,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-1.53
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,361,495,000
Inventory
$43,458,000
Receivables
$146,404,000
ST Investments
$344,477,000
EBIT TTM
$-148,768,000
Pretax Income TTM
$-175,213,000
Interest Exp TTM
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$674,414,016
EBITDA
$-166,215,008
Free Cash Flow
$5,082,750
Enterprise Value
$1,883,080,064
Total Cash
$432,004,000
Total Debt
$234,940,000
Shares Out
115,820,940
Trailing EPS
$-1.53
Book Value
$2.85
ROE
-50.0%
ROA
-11.1%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 655,353,000 -153,800,000 -136,227,000 804,326,000 463,860,000 -49,031,000
Dec 2024 605,220,000 -170,496,000 -168,627,000 1,240,784,000 880,605,000 -26,369,000
Dec 2023 509,338,000 -232,870,000 -207,043,000 1,146,129,000 783,633,000 -73,336,000
Dec 2022 537,840,000 -89,523,000 -92,534,000 1,191,648,000 750,478,000 30,788,000

TTM Snapshot

Revenues TTM
$547,020,000
NetIncome TTM
$-119,755,000
OpCashFlow TTM
$0
Assets (Latest)
$1,240,784,000
Forward EPS
$-1.17

Peers — same industry

TickerNameMarket CapLastDaily %
ESTA ESTABLISHMENT LABS HOLDINGS INC. $2.14B $72.64
AXGN Axogen, Inc. $2.20B $41.45
XRAY DENTSPLY SIRONA Inc. $2.00B $9.99
LMAT LEMAITRE VASCULAR INC $2.26B $98.71
TMDX TransMedics Group, Inc. $2.44B $70.46

News headlines (Yahoo Finance, 1h cache)

3 Overlooked Stocks Set to Soar in 2026
2026-05-05 13:05 · Yahoo
NovoCure Stock Shows Strength With RS Upgrade; Investors Should Watch For Next Entry
2026-05-04 20:25 · Yahoo
International Markets and NovoCure (NVCR): A Deep Dive for Investors
2026-05-04 13:15 · Yahoo
NovoCure Limited (NASDAQ:NVCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
2026-05-02 13:13 · Yahoo
NovoCure Limited Q1 2026 Earnings Call Summary
2026-05-01 00:45 · Yahoo
NovoCure (NVCR) Q1 2026 Earnings Transcript
2026-04-30 21:02 · Yahoo
Two Medical Stocks Skyrocket After Demolishing Views — And One Is About To Break Out
2026-04-30 20:06 · Yahoo
Sector Update: Health Care Stocks Gain Thursday Afternoon
2026-04-30 17:32 · Yahoo
NovoCure Q1 Earnings Call Highlights
2026-04-30 13:20 · Yahoo
NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates
2026-04-30 12:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.